 |
|
|
 |
|
Rationale:
- Muscle weakness, including acute flaccid paralysis, and changes in mental status in patients with encephalitis are predictors
of death and poor neurologic outcome.
|
|
Evidence:
- Only 28% of patients with WNV encephalitis and/or neuromuscular weakness in a Canadian series were discharged home without
additional support, and most had persistent neurologic deficits 30 days after discharge (29).
- Three out of 16 hospitalized, WNV antibody-positive patients had poliomyelitis-like acute flaccid paralysis in a 2002 Louisiana
series (30).
|
|
Comments:
- Case-fatality rates among patients hospitalized with neuroinvasive WNV illness during recent outbreaks of the currently circulating
strain of WNV in the U.S., Canada, and Israel have ranged from 12% to 18%. These case-fatality rates are greater than those
previously seen in the Middle East and Africa. This may be due to differences in the age structure or frequency of medical
risk factors in the nonimmune population or to the underlying virulence of the WNV strain. Although the specific reason is
not known, there has been a much higher incidence of encephalitis and a higher case-fatality rate than seen in previous outbreaks
(6; 31).
- Case-fatality rates have been shown to be higher among patients under age 50 and in those with more severe disease (2; 24; 26).
|
| FAQs |
|
|
|
Amy V. Bode, MD, MSPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Anthony A. Marfin, MD, MPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
James J. Sejvar, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Yanlin Tang, PhD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for
continuing medical education grand rounds and lectures given.
|
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|